Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Passing of Genmab A/S' Annual General Meeting23 Apr 2008
Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS15 Apr 2008
Major shareholder announcement7 Apr 2008
Genmab A/S Summons Annual General Meeting7 Apr 2008
Articles of Association of Genmab A/S dated April 1, 20083 Apr 2008
Capital Increase in Genmab as a Result of Employee Warrant Exercise1 Apr 2008
Genmab's 2007 Annual Report31 Mar 2008
Genmab Announces Year End 2007 Financial Results
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
31 Mar 2008
Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility13 Mar 2008
Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets3 Mar 2008
Genmab to Attend Two March Investor Conferences27 Feb 2008
Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance26 Feb 2008
  • Previous
  • 1
  • More pages
  • 113
  • 114
  • 115
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863